The chief executive of Mylan plans to defend the price of EpiPens before Congress on Wednesday, but will acknowledge that the drug maker should have foreseen consumer concern over rising costs, according to an advance copy of her remarks.
“Looking back, I wish we had better anticipated the magnitude and acceleration of the rising financial issues for a growing minority of patients who may have ended up paying the [list price] or more,” Heather Bresch plans to say. “We never intended this.”
Bresch is scheduled to testify before the House Committee on Oversight and Government Reform amid a public outcry over the price of EpiPens and congressional scrutiny.
Read Full Article »
